With billions in market potential, it’s hard to ignore the promise of female technology (femtech). Investor participation points to growth—though it may be slow given the current market environment. Dealmaking in female technology (femtech) is holding up fairly well, yet still undersized compared to other segments and its potential market size, particularly at the expansion stage. Competition from broader healthcare players and incumbents is a factor, but overall speaks to the femtech segment not getting the attention it deserves.
Read the full article: Femtech: Resilient and Poised to Grow //
Source: https://www2.deloitte.com/content/dam/Deloitte/us/Documents/audit/us-road-to-next-femtech.pdf